By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Latanoprost/timolol, also known as Xalacom, is a combination medication used to treat glaucoma that contains both timolol and latanoprost (which increases uveoscleral outflow of aqueous humour) (a beta blocker decreasing the production of aqueous fluid).
Eyedrops of the latanoprost-timolol solution are offered. It is used to lower intraocular pressure or open-angle glaucoma patients’ pressure inside their eyes (increased pressure in the eye).
A combo treatment called LATANOPROST+TIMOLOL that contains “ophthalmic medication” is used to treat disorders including glaucoma and ocular hypertension that cause elevated pressure in the eyes.
Ocular hypertension is a condition when the aqueous humour doesn’t drain properly, causing the eye’s pressure to be higher than normal (fluid inside the eye). Due to excessively high pressure inside the eye, glaucoma is an eye condition that damages the optic nerve. Untreated, this illness has the potential to cause permanent eyesight loss.
Latanoprost and Timolol are both found in LATANOPROST+TIMOLOL. Latanoprost, a prostaglandin analogue, increases the natural flow of fluid from the interior of the eye into the bloodstream to achieve its therapeutic effects.
As a result, the eye’s pressure is reduced. Timolol is a beta-blocker that lowers eye pressure by reducing the amount of fluid produced in the eye. Only the infected eye should be treated with LATANOPROST+TIMOLOL; prevent contact with the healthy eye.
The Global timolol latanoprost market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis.
Patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT) who need more than one medication to meet their target intraocular pressure undergo fixed-combination (FC) therapy (IOP).
Several FC treatments are being offered for the management of glaucoma. A frequently used FC is latanoprost/timolol (LTFC). A systematic review to examine the efficacy of LTFC and other FCs on decreasing IOP in patients with POAG and OHT.
In this meta-analysis, 16 trials were included. A moderate-quality meta-analysis revealed that LTFC had a similar mean IOP to that of a fixed combination of travoprost and timolol (TTFC) [mean difference (MD): 0.07 mmHg] and a fixed combination of dorzolamide and timolol (DTFC) [MD: 0.31 mmHg], as well as a similar IOP-fluctuation effect to that of TTFC Low-quality meta-analysis revealed increased IOP variation [MD 1.09 mmHg] and moderate-quality evidence revealed a higher mean IOP in the LTFC group when compared to the fixed combination of bimatoprost and timolol (BiTFC).
In POAG or OHT patients, LTFC is as effective as TTFC and DTFC but less effective than BiTFC in regulating mean IOP and IOP fluctuation. With the exception of one low-quality analysis that examined the IOP fluctuation of LTFC and BiTFC, the quality of our meta-analyses was moderate.
